Industry
Biotechnology
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Loading...
Open
2.08
Mkt cap
103M
Volume
16K
High
2.12
P/E Ratio
-10.05
52-wk high
2.55
Low
2.08
Div yield
N/A
52-wk low
1.12
Portfolio Pulse from
November 14, 2024 | 11:15 pm
Portfolio Pulse from
November 11, 2024 | 11:15 pm
Portfolio Pulse from Benzinga Insights
October 24, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
October 24, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 7:23 am
Portfolio Pulse from Benzinga Insights
October 11, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 8:39 am
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 7:23 am
Portfolio Pulse from Avi Kapoor
September 03, 2024 | 5:41 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.